ReviewFrontiers in neuroscience2020
Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07169747 (The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.Eating and weight disorders : EWD · 2025Pooled it
- Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Identification of a neural basis for anorexia nervosa.bioRxiv : the preprint server for biology · 2026Article
- Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms.Molecular and cellular biochemistry · 2025Review
- Effects of psilocybin on body weight, body composition, and metabolites in male and female mice.Physiology & behavior · 2024Article
- Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.Molecular psychiatry · 2024Article
- Innovative and Emerging Treatments for Anorexia Nervosa.Focus (American Psychiatric Publishing) · 2024Article
- Eating Disorders: Updates and Innovations.Focus (American Psychiatric Publishing) · 2024Article
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential.Molecular psychiatry · 2024Review
- Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.Trends in psychiatry and psychotherapy · 2024Review
- Molecular and Medical Aspects of Psychedelics.International journal of molecular sciences · 2023Review
- Article
- Gut Microbiota and Brain Alterations after Refeeding in a Translational Anorexia Nervosa Rat Model.International journal of molecular sciences · 2023Article
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023Review
- Body mass index (BMI) does not predict responses to psilocybin.Journal of psychopharmacology (Oxford, England) · 2023Article
- A next generation sequencing gene panel for use in the diagnosis of anorexia nervosa.Eating and weight disorders : EWD · 2022Article
- Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.Frontiers in neuroscience · 2022Review
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.BJPsych open · 2021Review
- Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN that relate to serotonergic signaling and cognitive inflexibility. Clinical trials using psychedelics in treatment-resistant depression have shown promising outcomes, although these studies are unable to circumvent some methodological biases. The first clinical trial to use psilocybin in patients with AN commenced in 2019, necessitating a better understanding of the neurobiological mechanisms through which psychedelics act. Animal models are beneficial in this respect, allowing for detailed scrutiny of brain function and behavior and the potential to study pharmacology without the confounds of expectancy and bias that are impossible to control for in patient populations. We argue that studies investigating the neurobiological effects of psychedelics in animal models, including the activity-based anorexia (ABA) rodent model, are particularly important to inform clinical applications, including the subpopulations of patients that may benefit most from psychedelic medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.